
Hong Kong, China as regulatory member of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use marks key step towards developing into international health and medical innovation hub
***************************************************************
The Health Bureau announced today (November 20) that Hong Kong, China has formally joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory member. The ICH is a key international platform for the harmonisation of technical standards for drug regulation. Hong Kong's formal accession to ICH membership signifies international recognition of its drug research and development (R&D) as well as regulatory standards. It will help further promote the development of the capabilities and mechanisms for the "primary evaluation" of innovative drugs, enable Hong Kong to participate deeply in the formulation of international rules on drug R&D and registration, and accelerate the development of Hong Kong into an international health and medical innovation hub.
At its assembly meeting held in Czech Republic on November 17, 2026, the ICH approved the admission of Hong Kong, China (represented by the Pharmacy and Poisons Board of Hong Kong) as its 20th regulatory member. Other ICH regulatory members include the National Medical Products Administration of China and the regulatory authorities of Europe, Switzerland, the United Kingdom and the United States.
The Secretary for Health, Professor Lo Chung-mau, said, "The Hong Kong Special Administrative Region (HKSAR) Government expresses its sincere gratitude to the country for its continued full support for Hong Kong's development into an international health and medical innovation hub. Hong Kong, China becoming an ICH regulatory member fully demonstrates the unique advantages of the 'one country, two systems' principle. Since becoming an ICH observer on October 31, 2023, Hong Kong has, with the country's strong support, devoted its full efforts to fulfilling all the requirements of the ICH, and was able to formally become an ICH regulatory member in just three years, significantly accelerating the process compared with the eight to 10 years estimated by the Government earlier with reference to international experience."
Professor Lo added, "Looking ahead, the HKSAR Government will, in accordance with the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026-2030), actively dovetail with the National 15th Five-Year Plan to support clinical R&D in biomedicine and optimise the evaluation and approval mechanism for innovative drugs, and drugs with urgent clinical use. The HKSAR Government will establish the Centre for Medical Products Regulation (CMPR) next month to build up capacity for independent drug evaluation and approval, and actively participate in international co-operation, with a view to developing Hong Kong into an international health and medical innovation hub and better integrating into and serving the overall national development."
The Director of Health, Dr Ronald Lam, said, "Joining the ICH marks an important milestone in Hong Kong's drug evaluation, approval and regulatory reform, and is particularly significant to the CMPR to be established soon. The CMPR will, in accordance with the technical requirements of the ICH, build up a professional team for independent evaluation and approval, enhance the efficiency of evaluating innovative drugs, and deploy experts to participate in the formulation and revision of ICH guidelines, contributing to the scientific advancement of drug regulation worldwide. Hong Kong is now both an ICH regulatory member and a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The CMPR will adopt a science-based approach and strive to become an internationally renowned regulatory authority."
The ICH is an authoritative international body for pharmaceutical harmonisation. The mission of the ICH is to harmonise global technical requirements for drug registration and to promulgate various guidelines on safety, efficacy and quality that are recognised as the highest international standards for the protection of public health. The PIC/S is a renowned international organisation comprising pharmaceutical regulatory authorities from multiple countries and regions. Its mission is to lead the international development, formulate standards for implementation, and adherence to harmonised Good Manufacturing Practice standards and quality systems among pharmaceutical regulatory authorities. Having passed the relevant assessment in 2015, Hong Kong, China formally became a PIC/S member with effect from January 1, 2016.
Ends/Friday, November 20, 2026
Issued at HKT 15:25
NNNN